Treatment-resistant and insufficiently treated depression and all-cause mortality following myocardial infarction

Scherrer, Jeffrey F.; Chrusciel, Timothy; Garfield, Lauren D.; Freedland, Kenneth E.; Carney, Robert M.; Hauptman, Paul J.; Bucholz, Kathleen K.; Owen, Richard R.; Lustman, Patrick J.

doi:10.1192/bjp.bp.111.096479

Cited by 63 publications

(45 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…(15) We followed a definition previously employed in retrospective cohort studies involving medical records. (16, 17) Patients were defined as having TRD if any of the following were recorded in the medical record: a) electroconvulsive therapy, b) MAOI prescription, c) two or more antidepressants (any SSRI, SNRI, TCA or “other” non-MAOI antidepressant) at the same time overlapping by at least 31 days, or d) augmentation therapy (i.e. prescription of a mood stabilizing or atypical antipsychotic after antidepressant treatment).…”

Section: Methodsmentioning

confidence: 99%

The influence of prescription opioid use duration and dose on development of treatment resistant depression

Scherrer

Salas

Sullivan

et al. 2016

Preventive Medicine

Self Cite

View full text Add to dashboard Cite

Long-term prescription opioid use is associated both with new-onset and recurrence of depression. Whether chronic opioid use interferes with depression management has not been reported, therefore we determined whether patients’ longer duration of opioid use and higher opioid dose are associated with new-onset treatment resistant depression (TRD) after controlling for confounding from pain and other variables. Data was obtained from Veteran Health Administration (VHA) de-identified patient medical records. We used a retrospective cohort design from 2000–2012. Eligible subjects (n=6,169) were 18–80 years of age, free of cancer and HIV, diagnosed with depression and opioid-free for the 24-month interval prior to the observation period. Duration of a new prescription for opioid analgesic was categorized as 1–30 days, 31–90 days and >90 days. Morphine-equivalent dose (MED) during follow-up categorized as ≤50 mg versus >50 mg per day. Pain and other sources of confounding were controlled by propensity scores and inverse probability of treatment weighting. Cox proportional hazard models were computed to estimate the association between duration and dose of opioid and onset of TRD. After removing confounding by weighting data, opioid use for 31–90 days and for >90 days, compared to 1–30 days, was significantly associated with new onset TRD (HR=1.25; 95%CI: 1.09–1.45 and HR=1.52; 95%CI: 1.32–1.74, respectively). MED was not associated with new onset TRD. The risk of developing TRD increased as time spent on opioid analgesics increased. Long-term opioid treatment of chronic pain may interfere with treatment of depression.

show abstract

Section: Methodsmentioning

confidence: 99%

The influence of prescription opioid use duration and dose on development of treatment resistant depression

Scherrer

Salas

Sullivan

et al. 2016

Preventive Medicine

Self Cite

View full text Add to dashboard Cite

show abstract

“…It is evidenced that depression is common after coronary event [27] and it continues to remain under recognized and poorly treated in cardiac population [28]. Previous research has shown that ACS patients benefit from cognitive behavioural therapy following an episode of myocardial infarction [29] and therefore, measuring emotional status will assists clinicians to identify depressive symptoms.…”

Section: Discussion Principal Resultsmentioning

confidence: 99%

Multidisciplinary Smartphone-Based Interventions to Empower Patients With Acute Coronary Syndromes: Qualitative Study on Health Care Providers’ Perspectives (Preprint)

Bashi¹,

Hassanzadeh²,

Varnfield³

et al. 2018

Preprint

View full text Add to dashboard Cite

show abstract

“…Scherrer and colleagues [81] found that post-MI patients with treatment-resistant depression had mortality intermediate between adequate treatment cases and inadequate treatment cases, but that they also had more co-morbid medical problems. They concluded that more research is necessary to determine whether changes in depression independently predict all-cause mortality.…”

Section: Future Prospectsmentioning

confidence: 97%

Management of Depression After Myocardial Infarction

Shapiro

2015

Curr Cardiol Rep

View full text Add to dashboard Cite

Depression in patients who have had a myocardial infarction is an important clinical problem because it is extremely common and because the comorbidity complicates depression treatment and worsens the cardiovascular prognosis. Studies of psychotherapy, exercise, pharmacotherapy, and collaborative care demonstrate that effective treatment of depression is possible but the strength of the effects seen in most studies is low, and cardiovascular and all-cause morbidity and mortality benefits have not been proven. Recent collaborative care studies have had promising outcomes. For pharmacotherapy, side effects, including bleeding and arrhythmia risks, require special attention. Recovery from depression is associated with better long-term cardiovascular prognosis, while treatment per se is not.

show abstract

Treatment-resistant and insufficiently treated depression and all-cause mortality following myocardial infarction

Cited by 63 publications

References 16 publications

The influence of prescription opioid use duration and dose on development of treatment resistant depression

The influence of prescription opioid use duration and dose on development of treatment resistant depression

Multidisciplinary Smartphone-Based Interventions to Empower Patients With Acute Coronary Syndromes: Qualitative Study on Health Care Providers’ Perspectives (Preprint)

Management of Depression After Myocardial Infarction

Contact Info

Product

Resources

About